Viewing Study NCT06026657


Ignite Creation Date: 2025-12-24 @ 6:51 PM
Ignite Modification Date: 2026-01-04 @ 12:01 AM
Study NCT ID: NCT06026657
Status: RECRUITING
Last Update Posted: 2025-07-08
First Post: 2023-08-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Sponsor: Margaret Gatti-Mays
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module